Overview
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — specifically the 12S rRNA gene — making it one of a newly characterized class of "mitochondria-derived peptides" (MDPs). It was identified by Pinchas Cohen and colleagues at the USC Leonard Davis School of Gerontology in 2015. MOTS-c circulates in the bloodstream and acts as a hormone-like signaling molecule. Research has shown that plasma MOTS-c levels decline with age and are significantly lower in individuals with type 2 diabetes and obesity, positioning it as a potentially important metabolic regulator. Its expression responds to exercise and caloric restriction.
Mechanism
MOTS-c primarily acts by translocating to the nucleus in response to cellular stress, where it regulates nuclear gene expression through interaction with AMPK and the AICAR/ZMP pathway. It promotes fatty acid oxidation, inhibits the folate-methionine cycle to redirect metabolic flux toward nucleotide biosynthesis, and activates AMPK — the cellular "energy sensor" — without requiring upstream AMP accumulation. These effects produce insulin sensitization, improved glucose uptake, and increased metabolic flexibility.
Research Areas
Side Effects (Preclinical)
- – No significant adverse effects reported in published animal studies
- – Human safety data is limited
Cautions
- – For research use only — no clinical approval
- – Relatively new compound (identified 2015); long-term effects unstudied
- – Interactions with exercise-induced signaling pathways not fully characterized
Menopause & Women's Health Relevance
Plasma MOTS-c levels are lower in post-menopausal women compared to pre-menopausal women at the same age, and correlate inversely with insulin resistance. The metabolic shift at menopause — increased visceral fat, reduced insulin sensitivity, elevated cardiovascular risk — maps directly onto MOTS-c's AMPK-activation research profile. Animal studies show MOTS-c administration prevents ovariectomy-induced metabolic dysfunction.
What the research shows
The original 2015 paper by Lee et al. established MOTS-c as a mitochondria-derived endocrine peptide, showing that it prevents obesity, improves insulin sensitivity, and activates AMPK in mouse models — effects comparable to exercise without physical activity (the “exercise mimicry” framing that has driven popular interest).
Subsequent research has shown that MOTS-c plasma levels correlate inversely with metabolic syndrome markers in human cohort studies, and that exercise itself increases MOTS-c levels, partly explaining exercise’s metabolic benefits through a previously unknown peptide-signaling mechanism.
References
- MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis — Lee C et al. (2015)
- Humanin and MOTS-c: Mitochondrial-Derived Peptides and the Regulation of Whole-Body Energy Homeostasis — Kim SJ et al. (2021)